AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9111873 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal mixture of Cupressus sempervirens and Cryptomeria japonica pollen
Number of subjects: 20
Study 9111873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8464252 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge planning from day 3 of hospital stay (n = 417)
Number of subjects: 835
Study 8464252 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge planning only with written physician request (n = 418)
Number of subjects: 835
Study 6705277 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of 1 ml (Group I)
Number of subjects: 215
Study 6705277 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of 2 ml (Group II)
Number of subjects: 215
Study 6705277 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 injections of 1 ml (Group III)
Number of subjects: 215
Study 30823913 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise training programme using minimal equipment, conducted six days per week with coaching from a health care professional during three home visits and regular telephone calls over one year.
Number of subjects: 120
Study 30823913 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise training programme using minimal equipment.
Number of subjects: 120
Study 30126781 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (Prevena)
Number of subjects: 119
Study 30126781 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 119
Study 27423166 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week Internet-based cognitive-behavioral intervention
Number of subjects: 139
Study 27423166 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 139
Study 24705980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel (GD)
Number of subjects: 0
Study 24705980 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine-docetaxel (CD)
Number of subjects: 0
Study 19875317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy (BSSO)
Number of subjects: 14
Study 19875317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular distraction osteogenesis (MDO)
Number of subjects: 14
Study 16269641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels
Number of subjects: 6713
Study 16269641 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein levels
Number of subjects: 6713
Study 11355380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined task (color and position cues)
Number of subjects: 0
Study 11355380 — intervention group
Group type: COMPARATOR
Intervention: Standard task (position cue)
Number of subjects: 0
Study 11355380 — intervention group
Group type: COMPARATOR
Intervention: Non-standard task (color cue)
Number of subjects: 0
Study 9531078 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy followed by simultaneous resection of primary and metastatic lesions (when feasible) and further chemotherapy
Number of subjects: 44
Study 9531078 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous surgical treatment of primary and metastatic tumor
Number of subjects: 44
Study 9531078 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment including chemotherapy and surgery
Number of subjects: 44
Study 9531078 — intervention group
Group type: COMPARATOR
Intervention: Comparison with contemporary patients with localized disease
Number of subjects: 44
Study 8033492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous torsemide
Number of subjects: 48
Study 8033492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral torsemide
Number of subjects: 48
Study 2688405 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 14
Study 2688405 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 1092576 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated influenza virus vaccine (ANN strain)
Number of subjects: 37
Study 1092576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30280651 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E
Number of subjects: 1786
Study 30280651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1786
Study 27278062 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN-DBS
Number of subjects: 22
Study 27278062 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided STN-DBS
Number of subjects: 22
Study 27278062 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided STN-DBS
Number of subjects: 22
Study 27278062 — intervention group
Group type: COMPARATOR
Intervention: Unilateral STN-DBS
Number of subjects: 22
Study 27278062 — intervention group
Group type: COMPARATOR
Intervention: Off stimulation
Number of subjects: 22
Study 25008799 — intervention group
Group type: COMPARATOR
Intervention: Naso-gastric infusion of 500mL/0kJ water (Stomach distention)
Number of subjects: 14
Study 25008799 — intervention group
Group type: COMPARATOR
Intervention: Naso-gastric infusion of 500mL/1770kJ chocolate milk (Stomach distention with caloric content)
Number of subjects: 14
Study 25008799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 500mL/1770kJ chocolate milk (Stomach distention with caloric content and oral exposure)
Number of subjects: 14
Study 22656075 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training package including frame-of-reference and rater error training
Number of subjects: 0
Study 22656075 — intervention group
Group type: COMPARATOR
Intervention: Standard training package involving overview, modeling, practice, and feedback
Number of subjects: 0
Study 22656075 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive training package
Number of subjects: 0
Study 21050539 — intervention group
Group type: EXPERIMENTAL
Intervention: Older SSc patients
Number of subjects: 264
Study 18545166 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball
Number of subjects: 16
Study 18545166 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board
Number of subjects: 16
Study 18545166 — intervention group
Group type: COMPARATOR
Intervention: Dyna Disc
Number of subjects: 16
Study 18545166 — intervention group
Group type: COMPARATOR
Intervention: BOSU ball
Number of subjects: 16
Study 18545166 — intervention group
Group type: COMPARATOR
Intervention: Stable base
Number of subjects: 16
Study 15705690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artemether
Number of subjects: 103
Study 15705690 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 103
Study 14514538 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 10
Study 14514538 — intervention group
Group type: COMPARATOR
Intervention: Aero position
Number of subjects: 10
Study 10368486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of instruments (vacuum first, then forceps, or vice versa)
Number of subjects: 34
Study 10368486 — intervention group
Group type: COMPARATOR
Intervention: Vacuum group
Number of subjects: 34
Study 10368486 — intervention group
Group type: COMPARATOR
Intervention: Forceps group
Number of subjects: 34
Study 10368486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential group
Number of subjects: 34
Study 8888321 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mg silver acetate lozenge
Number of subjects: 500
Study 8888321 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 500
Study 2058340 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef 2 g single-dose prophylaxis
Number of subjects: 190
Study 2058340 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 190
Study 6093312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol
Number of subjects: 21
Study 6093312 — intervention group
Group type: COMPARATOR
Intervention: Saline aerosol (Control)
Number of subjects: 21
Study 31395391 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program
Number of subjects: 388
Study 29026961 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal subtotal septal reconstruction (ECS)
Number of subjects: 40
Study 29026961 — intervention group
Group type: COMPARATOR
Intervention: In situ septoplasty with asymmetric spreader grafts (ISS)
Number of subjects: 40
Study 26742606 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive care (n=99)
Number of subjects: 299
Study 26742606 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary care (n=101)
Number of subjects: 299
Study 26742606 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) (n=99)
Number of subjects: 299
Study 24528484 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based self-management course
Number of subjects: 0
Study 24528484 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22983369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 20
Study 22983369 — intervention group
Group type: COMPARATOR
Intervention: Warm Water (WW)
Number of subjects: 20
Study 20595283 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based intervention
Number of subjects: 0
Study 20595283 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapies
Number of subjects: 0
Study 20595283 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-based intervention
Number of subjects: 0
Study 17184370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 0
Study 17184370 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding
Number of subjects: 0
Study 17184370 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit retraining
Number of subjects: 0
Study 17184370 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed voiding
Number of subjects: 0
Study 15923248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate withdrawal (S)
Number of subjects: 497
Study 15923248 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment with salmeterol and fluticasone propionate (SFC)
Number of subjects: 497
Study 11864664 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone 100 mg daily for 4 months
Number of subjects: 80
Study 11864664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10715910 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (Cytotec‐Searle) vaginally (group M, n = 30)
Number of subjects: 64
Study 10715910 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (group Ox, n = 34)
Number of subjects: 64
Study 7566021 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine containing sitostanol ester (1.8 or 2.6 g of sitostanol per day)
Number of subjects: 153
Study 7566021 — intervention group
Group type: COMPARATOR
Intervention: Control group (margarine without sitostanol ester)
Number of subjects: 153
Study 2090399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendazac lysine (anti-cataract drug)
Number of subjects: 43
Study 345462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 206
Study 345462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 31299087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically apparent AKs
Number of subjects: 26
Study 31299087 — intervention group
Group type: EXPERIMENTAL
Intervention: AKs
Number of subjects: 26
Study 28024935 — intervention group
Group type: COMPARATOR
Intervention: Nitrate (140 mL·day−1 NO3−‐rich beetroot juice, 8.4 mmol NO3−·day−1)
Number of subjects: 9
Study 28024935 — intervention group
Group type: COMPARATOR
Intervention: Nitrate + Iodide (140 mL·day−1 NO3−‐rich beetroot juice and 450 μg potassium iodide·day−1)
Number of subjects: 9
Study 28024935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate + Iodide
Number of subjects: 9
Study 28024935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate
Number of subjects: 9
Study 25896114 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise videogames (EVGs) for 12 weeks
Number of subjects: 0
Study 25896114 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised standard exercise for 12 weeks
Number of subjects: 0
Study 25896114 — intervention group
Group type: COMPARATOR
Intervention: Control condition for 12 weeks
Number of subjects: 0
Study 23555873 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic visual stimulation at 10.6 Hz
Number of subjects: 0
Study 23555873 — intervention group
Group type: COMPARATOR
Intervention: Rhythmic visual stimulation at control frequencies (3.9 Hz, 7.1 Hz, 14.2 Hz)
Number of subjects: 0
Study 20634036 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drain (Group B)
Number of subjects: 100
Study 20634036 — intervention group
Group type: COMPARATOR
Intervention: No wound drain (Group A)
Number of subjects: 100
Study 19363857 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIN/RA (clindamycin 1.2% and tretinoin 0.025%)
Number of subjects: 45
Study 19363857 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tretinoin gel
Number of subjects: 45
Study 19363857 — intervention group
Group type: COMPARATOR
Intervention: 0.1% adapalene gel
Number of subjects: 45
Study 16709386 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (loading dose of 12 microg/kg followed by 24-hour infusion of 0.2 microg/kg per min)
Number of subjects: 41
Study 16709386 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (24-hour infusion of 7.5 microg/kg per min)
Number of subjects: 41
Study 15298561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite-impermeable mattress encasings and educational package
Number of subjects: 696
Study 15298561 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic information about allergies)
Number of subjects: 696
Study 11776446 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 J/cm2 treatment group
Number of subjects: 40
Study 11776446 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 J/cm2 treatment group
Number of subjects: 40
Study 11776446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 11776446 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study 9621294 — intervention group
Group type: EXPERIMENTAL
Intervention: OTZ (0.5 g three times a day orally with meals)
Number of subjects: 20
Study 9621294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7943083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen for 20 minutes
Number of subjects: 20
Study 7943083 — intervention group
Group type: COMPARATOR
Intervention: 40% oxygen for 20 minutes
Number of subjects: 20
Study 7943083 — intervention group
Group type: COMPARATOR
Intervention: 40% oxygen for 45 minutes
Number of subjects: 20
Study 3591872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral acetylcholine during the operative procedure
Number of subjects: 36
Study 3591872 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 36
Study 31560066 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide (240 mg daily)
Number of subjects: 1207
Study 31560066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 29198449 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily for 14 days
Number of subjects: 24
Study 29198449 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive alone (reference)
Number of subjects: 24
Study 27092703 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 40
Study 27092703 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 40
Study 25303114 — intervention group
Group type: EXPERIMENTAL
Intervention: Data mining approach to post-stroke mortality prediction
Number of subjects: 0
Study 25303114 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant risk factors
Number of subjects: 0
Study 25303114 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive classification models
Number of subjects: 0
Study 21747129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electric breast pumping
Number of subjects: 68
Study 21747129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand expression
Number of subjects: 68
Study 21747129 — intervention group
Group type: COMPARATOR
Intervention: Breast pumping
Number of subjects: 68
Study 20231298 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP)
Number of subjects: 405
Study 20231298 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 405
Study 18166828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 0
Study 15266201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15266201 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative research designs and psychosocial treatments
Number of subjects: 0
Study 11124288 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 28
Study 11124288 — intervention group
Group type: COMPARATOR
Intervention: Timolol hemihydrate
Number of subjects: 28
Study 9357184 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg tid for 10 days, followed by placebo for 50 days)
Number of subjects: 45
Study 9357184 — intervention group
Group type: EXPERIMENTAL
Intervention: Isapghul (10 g bid for 60 days)
Number of subjects: 45
Study 9357184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 capsule bid for 60 days)
Number of subjects: 45
Study 8479248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative fraction absorbed‐time profile method of paracetamol
Number of subjects: 0
Study 8479248 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional area under the curve method of paracetamol
Number of subjects: 0
Study 8479248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, codeine, and metoclopramide with neostigmine
Number of subjects: 0
Study 8479248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, codeine, and metoclopramide without neostigmine
Number of subjects: 0
Study 3083092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1‐mg dose of leuprolide
Number of subjects: 6
Study 3083092 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous 1‐mg dose of leuprolide
Number of subjects: 6
Study 3083092 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intravenous and subcutaneous administration
Number of subjects: 6
Study 3671256 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 18
Study 3671256 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude (4846 m)
Number of subjects: 18
Study 3671256 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test maintaining heart rate at 85% of maximum for 15 minutes
Number of subjects: 18
Study 3671256 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 31058342 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-care model
Number of subjects: 72
Study 31058342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 28487089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-incision THA
Number of subjects: 71
Study 28487089 — intervention group
Group type: COMPARATOR
Intervention: mini-posterior THA
Number of subjects: 71
Study 26152248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated screws
Number of subjects: 58
Study 26152248 — intervention group
Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 58
Study 26152248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 23316876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (PO) therapy
Number of subjects: 60
Study 23316876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) therapy
Number of subjects: 60
Study 23316876 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) therapy
Number of subjects: 60
Study 23316876 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 60
Study 21971723 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 8
Study 21971723 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position
Number of subjects: 8
Study 18378313 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation (n = 595)
Number of subjects: 1191
Study 18378313 — intervention group
Group type: COMPARATOR
Intervention: Medication (n = 596)
Number of subjects: 1191
Study 18378313 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analogues (PGAs)
Number of subjects: 1191
Study 17234108 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-828L 5 g/d for 56 days
Number of subjects: 84
Study 17234108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15332397 — intervention group
Group type: COMPARATOR
Intervention: Fixed CPAP
Number of subjects: 12
Study 15332397 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSet
Number of subjects: 12
Study 15332397 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizon
Number of subjects: 12
Study 15332397 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtuoso
Number of subjects: 12
Study 10999439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng-treated group (7 patients)
Number of subjects: 17
Study 10999439 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (10 patients)
Number of subjects: 17
Study 10999439 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 normotensive subjects)
Number of subjects: 17
Study 10999439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion
Number of subjects: 17
Study 9540780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (INR 2.5)
Number of subjects: 177
Study 9540780 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin 0.2 ml bid (8.00 and 20.00)
Number of subjects: 177
Study 9540780 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin (0.5 ml at 20.00)
Number of subjects: 177